ClinicalTrials.gg
RecruitingNCT04713722ELSUpdated Nov 2, 2026

Early Life Stress and Depression: Molecular and Functional Imaging

An observational study in Depression and Trauma, Psychological, sponsored by Mclean Hospital. Recruiting at 1 site in United States. Open to female participants aged 20 Years to 32 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Mclean Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.
Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
160
Ages
20 Years to 32 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in Depression by Mclean Hospital — 8 open to participants now, 10 under way, none of them phase 3. Depression · Mclean Hospital.

Planned enrollment
3rd of 10
160 · median 112
Started
2021
with 3 others
Observational
10 of 41
1 open now
Registered
31st of 41
by date

Among the 41 studies in Depression by Mclean Hospital, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2021, is one of 10 observational ones, and was the 31st registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

8 of the 41 studies in Depression by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 20 Years to 32 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Depression by Mclean Hospital, or all of them as a file.
02

Study summary

Severe childhood adversity accounts for a large portion of psychiatric illness, and an increased risk for major depressive disorder (MDD). For some individuals, childhood adversity has negative psychological and medical consequences; others preserve mental and physical health despite such experiences (they are resilient). In spite of this, little is known about the neurobiological mechanisms related to childhood adversity, especially oxidative stress abnormalities in the brain. To fill this gap, this study combines functional, structural, and molecular imaging approaches to examine the role of oxidative stress abnormalities related to childhood adversity.

Read the detailed description

Epidemiological studies have shown that severe childhood adversity explains 32-44% of psychiatric disorders, and is associated with 4.6-fold risk for MDD later in life. In spite of these epidemiological data, the neurobiological underpinnings associated with maladaptive sequelae of severe childhood adversity as well as resilience remain largely unknown.

Preclinical research suggests that early adversity leads to (1) structural abnormalities in brain regions critically implicated in stress regulation; (2) increased oxidative stress; and (3) glutamatergic abnormalities. The current research protocol is designed to prospectively test the contributions of these abnormalities in individuals exposed to severe childhood adversity.

Improving our understanding of neurobiological mechanisms associated with different childhood adversity outcomes is of paramount importance in order to (1) identify individuals at risk for psychopathology and maladaptive behavior, (2) prevent re-victimization, and (3) develop more targeted therapeutic interventions.

03

Conditions studied

  • Depression
  • Trauma, Psychological
04

Who can participate

Ages eligible
20 Years to 32 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy controls, those with depression (current or remitted), and those with depression and history of childhood adversity

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of all races and ethnic origins
  • Ages from 20 to 32
  • Right-handed
  • Capable of providing written
  • Currently unmedicated. Note that this criterion applies at enrollment only, and subjects will be informed that they can continue to be in the study if they begin a new medication after enrollment.
  • Normal or corrected-to-normal vision and hearing
  • Fluency in written and spoken English
  • Absence of first-degree relatives with a history of a psychotic disorder or psychotic symptoms; (adopted individuals are eligible to participate but we will probe about family history in case such information is available to the adopted subject)

Exclusion criteria

Exclusion Criteria:

  • Participants with suicidal ideation where continued study participation is deemed unsafe by the study clinician (these participants will be immediately referred to appropriate clinical treatment)
  • Pregnant women, or women of who have a positive result on a urine pregnancy test
  • Failure to meet MRI safety requirements including but not limited to any metal implants or prostheses that cannot be removed, or exposure to shrapnel
  • Claustrophobia or severe anxiety that might impact participation in neuroimaging
  • Injury or movement disorder that may make it difficult to lie still in the scanner
  • Any current recreational/illicit drug use as assessed by a urine drug test (covering cocaine, cannabinoids, opiates, amphetamines, methamphetamines, phencyclidine, MDMA, benzodiazepines, methadone, oxycodone, tricyclic antidepressants, and barbiturates)
  • Use of drug or herbal supplement for depression (e.g., St. John's Wort or SAMe) of those that could affect stress response
  • Use of any medication in the 24 hours prior to the Scanning procedure (including antibiotics, asthma inhalants, pain relievers, antihistamines, or over-the-counter medications).
  • Recent use (within 3 weeks) or any medication that affects blood flow or blood pressure, or which is vasodilating/vasoconstricting
  • Use of Melatonin within 5 days of the Scanning procedure
  • Metformin use in the past 6 months (for either clinical care or as part of research)
  • Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine (hypothyroidism), neurologic, disease (such as Lyme, Crohn's), or hematologic disease
  • Current infectious illness (either transient or chronic); Current episode of allergic reaction or asthma
  • Hemophilia; Diabetes with poor glucose control; History of chronic migraine (> 15 days/mo.); History or current diagnosis of dementia
  • History of seizure disorder
  • Any history of significant head injury or concussion
  • Past/current diagnosis of: OCD, ADHD, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders NOS, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, autism or any other pervasive developmental disorder, organic mental disorder, anorexia, binge eating disorder or bulimia (however a history of bulimia or binge eating disorder is allowable if it has been in remission for at least two years)
  • History of moderate or severe substance or alcohol use disorder; or, mild substance or alcohol use disorder within the last 12 months (with the exception of cocaine or stimulant abuse, which will lead to automatic exclusion).
  • History of ECT
  • Patient is clinically unstable, in the judgment of the clinician
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • MDD/childhood adversity group

    subjects with current MDD who experienced childhood adversity

  • rMDD/ childhood adversity

    subjects with a history of MDD who experienced childhood adversity

  • MDD

    subjects in a current episode of MDD, with no history of childhood adversity

  • Healthy Control

    healthy control subjects, with no history of childhood adversity

06

What researchers measure

Primary outcomes

  1. Immuno-oxidative abnormalities

    Redox ratio and glutamate metabolites in the prefrontal cortex

    Time frame: Baseline

Secondary outcomes

  1. Blood oxygen level dependent (BOLD) activation

    Prefrontal cortex activation during a reward task

    Time frame: Baseline

  2. Blood oxygen level dependent (BOLD) activation in emotional processing

    Prefrontal cortex activation during an emotional processing task

    Time frame: Baseline

  3. Peripheral inflammation

    Stress-related pro-inflammatory transcription control pathways

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Apr 2027, 74 months after the start.

Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 74 months is above that.

Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jun 2026 → Apr 2027 and completion Jun 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2021
First posted
Jan 19, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Apr 30, 2027was Jun 2026
CompletionEst.
Apr 30, 2027was Jun 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Apr 30, 2027
Nov 2, 2026
Study completion
Jun 30, 2026→Apr 30, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Jun 30, 2026→Apr 30, 2027
    Study completion Jun 30, 2026→Apr 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04713722
Lead sponsor
Mclean Hospital
Responsible party
Diego Pizzagalli (Professor, Harvard Medical School; Director, Mclean Hospital) — Principal investigator
First posted
Jan 19, 2021
Start date
Feb 1, 2021
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Aliza Brown
Contact
abrown98@mclean.harvard.edu
617-855-2589
Emma Palermo
Contact
ehpalermo@mclean.harvard.edu
617-855-4412
Diego Pizzagalli, PhD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion